Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin

Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its polyethylene glycol recombinant human somatropin, a long-acting somatropin, for the treatment of idiopathic short stature (ISS).

Understanding Idiopathic Short Stature (ISS)
Idiopathic short stature (ISS) is a collective term for a group of highly heterogeneous dwarfism diseases with an unclear etiology. It refers to children with a height below 2 standard deviations (SD) of the average height for their age, gender, and race, or below the 3rd percentile (P3, -1.88 SD). These children have normal birth length, weight, and body mass ratio, and show no evidence of systemic, endocrine, nutritional, chromosomal abnormalities, or genetic variations.

Changchun High & New’s Innovation in Growth Hormone Therapy
Changchun High & New’s product is the world’s first long-acting growth hormone specifically designed for ISS. This innovation significantly improves pediatric medication compliance by eliminating the need for frequent administration, a common challenge in treating growth-related conditions in children.- Flcube.com

Fineline Info & Tech